At a glance
ClinicalIndex Comparison RecordN/ACompleted· 140 enrolled
Drug / intervention
Enbrel treatmentother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Observational Study of the Real Life Management of the Psoriasis Patients Treated With Enbrel According to the New Reimbursement Criteria - Beflex Study
In Brief
An observational study evaluating Enbrel treatment for Plaque Psoriasis Patients. Completed, enrolled 140 participants across 1 site.
Detailed Summary
With the new reimbursement criteria, we want: To describe the average treatment duration of patients with Enbrel expressed as a number of weeks/year. To describe the number of patients who receive continuous treatment To describe the number of patients who receive intermittent treatment To describe the number of weeks off treatment
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis Patients
CountriesBelgium
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2011
First PostedMar 2012
Primary CompletionJun 2013
TodayJul 2026
First PostedMar 19, 2012
Enrollment StartSep 1, 2011
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 14.3 years ago
Interventions
Enbrel treatmentother
Enbrel SC 50mg once weekly or 25mg twice weekly